Bicycle Therapeutics (BCYC) Operating Leases (2019 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Operating Leases came in at $13.7 million in Q2 2026, up 675.07% YoY from $1.8 million in Q2 2025, and down 1.4% on a QoQ basis from $13.9 million in Q1 2026.
Bicycle Therapeutics (BCYC) Operating Leases (2019 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 8 years of Operating Leases data on file, last reported at $13.7 million in Q2 2026.
- Quarterly Operating Leases rose 675.07% year-over-year to $13.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $13.7 million (up 675.07% YoY) and the FY2025 annual result came in at $14.1 million, up 253.28% from the prior year.
- Operating Leases declined to $13.7 million in Q2 2026, from $13.9 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $14.4 million in Q1 2023 to a low of $981000.0 in Q3 2025.
- A 5-year average of $9.2 million and a median of $10.7 million in 2022 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2025 — Operating Leases sank 82.27% — and 2026, when it soared 675.07%.
- Tracing BCYC's Operating Leases over 5 years: stood at $10.9 million in 2022, then retreated by 13.81% to $9.4 million in 2023, then plunged by 57.47% to $4.0 million in 2024, then surged by 253.28% to $14.1 million in 2025, then slipped by 2.95% to $13.7 million in 2026.
- The last three Operating Leases figures came in at $13.7 million (Q2 2026), $13.9 million (Q1 2026), and $14.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.68 Mn |
| Mar 31, 2026 | 13.87 Mn |
| Dec 31, 2025 | 14.10 Mn |
| Sep 30, 2025 | 981,000.00 |
| Jun 30, 2025 | 1.77 Mn |
| Mar 31, 2025 | 2.61 Mn |
| Dec 31, 2024 | 3.99 Mn |
| Sep 30, 2024 | 5.53 Mn |
| Jun 30, 2024 | 6.73 Mn |
| Mar 31, 2024 | 8.05 Mn |
| Dec 31, 2023 | 9.38 Mn |
| Sep 30, 2023 | 10.42 Mn |
| Jun 30, 2023 | 11.88 Mn |
| Mar 31, 2023 | 14.39 Mn |
| Dec 31, 2022 | 10.89 Mn |
| Sep 30, 2022 | 11.00 Mn |
| Jun 30, 2022 | 12.50 Mn |
| Mar 31, 2022 | 14.09 Mn |
| Dec 31, 2021 | 12.08 Mn |
| Sep 30, 2021 | 2.50 Mn |